Updates in AL amyloidosis

Raymond Comenzo MD, of Tufts University School of Medicine, Boston, MA, discusses key updates in the amyloid light-chain (AL) amyloidosis field, including the Can2007, TOURMALINE-AL1, and ANDROMEDA studies, as well as current studies evaluating belantamab mafodotin, and antibody-drug conjugates for this indication. This interview was recorded via an online conference call with the Video Journal of Hematological Oncology (VJHemOnc).